By Stephanie Brown HealthDay ReporterFRIDAY, May 23, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...

A new study highlights the Cardio-Ankle Vascular Index (CAVI) as a powerful tool for predicting COPD progression and outcomes ...

Explore the future of the Chronic Obstructive Pulmonary Disease (COPD) market with our comprehensive report. This forecast model covers the 7 major markets from 2023 to 2033, predicting a CAGR of 10%, ...

Approval of Nucala marks the first biologic approved for chronic obstructive pulmonary disease patients with blood eosinophil counts as low as ≥150 cells/μL.

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a multi-year ...

GSK’s Nucala receives US FDA approval for use in adults with chronic obstructive pulmonary disease: London, UK Saturday, May 24, 2025, 11:00 Hrs [IST] GSK plc announced that the ...

Certain groups of physical multimorbidity may be associated with a higher risk of subsequent depression, according to a recent study.

Women with COPD, asthma, and OSA may go undiagnosed or without proper care because their symptomatology differs from the male ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

(RTTNews) - GSK plc. (GSK, GSK.L) announced that the US Food and Drug Administration has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately ...

A new study published in the International Journal of Chronic Obstructive Pulmonary Disease showed that regardless of ...